The biotechnology sector is at a critical crossroads, marked by rapid technological transformations and significant economic challenges. The integration of artificial intelligence (AI) into research and development (R&D) processes has become an essential strategic lever to overcome the obstacles posed by the "patent cliff," which threatens to reduce industry revenues by $400 billion. Recent initiatives, such as the alliance between Novo Nordisk and AWS for agentic AI integration in drug discovery, illustrate the transformative potential of these technologies.